Compare MLCI & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLCI | VANI |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.0M | 81.2M |
| IPO Year | N/A | 2014 |
| Metric | MLCI | VANI |
|---|---|---|
| Price | $8.34 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 49.1K | ★ 167.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,823,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 63.13 | N/A |
| 52 Week Low | $6.97 | $0.91 |
| 52 Week High | $8.75 | $1.92 |
| Indicator | MLCI | VANI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.11 |
| Support Level | N/A | $1.25 |
| Resistance Level | N/A | $1.55 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 56.67 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The Company's reporting segments include asset management and insurance. The asset management segment reflects the Company's historical operations through its subsidiaries, including ML Management, and the insurance segment represents Ability's operations. The Company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The insurance business is operated by Ability. Ability's insurance business consists of premium revenue from long term care insurance policies.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.